Sumatriptan Succinate Injection
Product Images NDC 62332-656

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 62332-656). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sumatriptan-4mg-carton-1s (Sumatriptan 4mg Carton 1s)

Packaging label for Sumatriptan Injection, USP 4 mg/0.5 mL subcutaneous injection by Alembic Pharmaceuticals Inc. The label details a single-dose autoinjector system containing 1 prefilled syringe of 0.5 mL solution per carton. Includes step-by-step instructions for use with illustrations, storage instructions, and manufacturing information indicating the product is made in India.*

FDA Label Image

Sumatriptan-4mg-carton-2s (Sumatriptan 4mg Carton 2s)

Packaging label for Sumatriptan Injection, USP 4 mg/0.5 mL by Alembic Pharmaceuticals Inc. The product is a subcutaneous injection supplied as a single-dose autoinjector system with 2 prefilled syringes per carton. The label includes patient instructions for use and storage guidance, highlighting the 4 mg/0.5 mL strength and labeling it for subcutaneous injection only.*

FDA Label Image

Sumatriptan-4mg-pen-label (Sumatriptan 4mg Pen Label)

Label for Sumatriptan Injection, USP 4 mg/0.5 mL subcutaneous injection by Alembic Pharmaceuticals Inc. It shows a single-dose autoinjector system containing 0.5 mL with 5.6 mg of sumatriptan succinate equivalent to 4 mg sumatriptan. The label includes storage instructions, barcode, and lot/expiration placeholders.*

FDA Label Image

Sumatriptan-4mg (Sumatriptan 4mg)

SUMATRIPTAN SUCCINATE 6 mg/0.5 mL subcutaneous injection in a prefilled syringe. The syringe has a white plunger and a transparent barrel showing the liquid medication inside. The label includes the product name, strength, and the labeler Alembic Pharmaceuticals Inc.*

FDA Label Image

Sumatriptan-6mg-carton-1s (Sumatriptan 6mg Carton 1s)

The packaging label for Sumatriptan Injection, USP 6 mg/0.5 mL by Alembic Pharmaceuticals Inc. It is a single-dose prefilled syringe for subcutaneous injection, presented as a single auto-injector system. The carton includes dosage instructions and cautions, batch, and storage information, and is labeled for prescription use only.*

FDA Label Image

Sumatriptan-6mg-carton-2s (Sumatriptan 6mg Carton 2s)

Packaging label for Sumatriptan Injection, USP 6 mg/0.5 mL, a subcutaneous injection by Alembic Pharmaceuticals Inc. The label shows a single dose autoinjector system with 2 prefilled syringes per carton. Usage instructions are illustrated, and the label includes storage instructions and manufacturer details from Alembic Pharmaceuticals Limited, India.*

FDA Label Image

Sumatriptan-6mg-pen-label (Sumatriptan 6mg Pen Label)

Sumatriptan Injection, USP 6 mg/0.5 mL subcutaneous injection label from Alembic Pharmaceuticals Inc. The label states this is a single dose autoinjector system with a prefilled syringe containing 6 mg sumatriptan and 3.5 mg sodium chloride. It is sterile and nonpyrogenic, for prescription use only, storing instructions included, and manufactured in India.*

FDA Label Image

Sumatriptan-6mg (Sumatriptan 6mg)

SUMATRIPTAN SUCCINATE 6 mg/0.5 mL subcutaneous injection in a prefilled syringe. The syringe features a white body with a blue cap and a clear injector end. The label indicates the strengths and manufacturer Alembic Pharmaceuticals Inc.*

FDA Label Image

Sumatriptan-features2 (Sumatriptan Features2)

An instructional illustration showing a pre-filled auto-injector of sumatriptan succinate in three stages: (a) with cap before injection, (b) after cap removal before injection, and (c) after injection with the needle fully deployed.*

FDA Label Image

Sumatriptan-figure-1 (Sumatriptan Figure 1)

Line graph depicting the estimated percentage of patients with relief over time (minutes) comparing sumatriptan and placebo groups. The graph shows higher relief percentages for sumatriptan versus placebo, with data points up to 25 minutes post-administration.*

FDA Label Image

Sumatriptan-ifu-fig-a (Sumatriptan Ifu Fig A)

An instructional illustration depicting a gloved hand holding a prefilled syringe for subcutaneous injection. An inset highlights proper eye protection or visual attention during preparation or administration of the injection, related to sumatriptan succinate injection use.*

FDA Label Image

Sumatriptan-ifu-fig-b (Sumatriptan Ifu Fig B)

Illustration showing recommended injection sites for subcutaneous administration of sumatriptan succinate. Sites are marked on the upper arms and upper outer buttocks, labeled with numbers '1' and '2' to indicate different injection locations.*

FDA Label Image

Sumatriptan-ifu-fig-c (Sumatriptan Ifu Fig C)

An illustration showing the proper technique for subcutaneous injection into the thigh. The image depicts a hand holding a syringe, preparing to inject into the outer thigh area of a bent leg sitting on a chair.*

FDA Label Image

Sumatriptan-ifu-fig-d (Sumatriptan Ifu Fig D)

An instructional illustration demonstrating the handling of a subcutaneous injection device. It shows a hand holding a prefilled injection pen angled downward and about to remove the protective cap from the needle end with the other hand, indicated by a downward arrow.*

FDA Label Image

Sumatriptan-ifu-fig-e (Sumatriptan Ifu Fig E)

An instructional illustration showing two close-up views of a grey injector component held between fingers. The left panel, marked with a check mark, displays the correct orientation or positioning of the injector piece. The right panel, marked with an X, shows an incorrect orientation or positioning for the same injector piece.*

FDA Label Image

Sumatriptan-ifu-fig-f (Sumatriptan Ifu Fig F)

An instructional illustration showing a gloved hand holding a subcutaneous injection device at a 90-degree angle to the skin, demonstrating the proper technique for administering a SUMATRIPTAN SUCCINATE injection.*

FDA Label Image

Sumatriptan-ifu-fig-g (Sumatriptan Ifu Fig G)

Instructional diagram showing hand positioning and angle for subcutaneous injection of Sumatriptan Succinate injection. The first image shows holding the syringe at a 90-degree angle to the skin, and the second depicts pressing down to administer the injection.*

FDA Label Image

Sumatriptan-ifu-fig-h (Sumatriptan Ifu Fig H)

An instructional illustration showing a gloved hand holding a sumatriptan succinate injection vial with an arrow indicating downward pressure on the vial stopper. A timer icon indicating 5 seconds is displayed, suggesting a step involving pressing and holding the stopper for that duration as part of the subcutaneous injection procedure.*

FDA Label Image

Sumatriptan-ifu-fig-i (Sumatriptan Ifu Fig I)

Illustration showing two stages of a subcutaneous injection device containing Sumatriptan Succinate. The left side depicts the device before injection with the syringe inside a protective casing, and the right side shows the syringe after the plunger is pressed down, indicating medication administration.*

FDA Label Image

Sumatriptan-ifu-fig-j. (Sumatriptan Ifu Fig J)

An instructional illustration showing a hand holding a subcutaneous injection device for sumatriptan succinate. The image demonstrates removing a cap by pulling upward and rotating the device 90 degrees before injection.*

FDA Label Image

Sumatriptan-ifu-fig-k (Sumatriptan Ifu Fig K)

Illustration showing a gloved hand disposing of a used injection pen into a sharps container designed for safe needle disposal. The image emphasizes proper disposal technique for subcutaneous injection devices like the sumatriptan succinate injection pen.*

FDA Label Image

Sumatriptan-structure (Sumatriptan Structure)

Chemical structure of sumatriptan succinate showing its molecular connectivity and functional groups. The diagram includes the sulfonamide, indole, and succinate moieties as part of the structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.